Loading...
Please wait, while we are loading the content...
Similar Documents
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
| Content Provider | Scilit |
|---|---|
| Author | Rea, Delphine Nicolini, Franck E. Tulliez, Michel Guilhot, François Guilhot, Joelle Guerci-Bresler, Agnès Gardembas, Martine Coiteux, Valérie Guillerm, Gaelle Legros, Laurence Etienne, Gabriel Pignon, Jean-Michel Villemagne, Bruno Escoffre-Barbe, Martine Ianotto, Jean-Christophe Charbonnier, Aude Johnson-Ansah, Hyacinthe Noel, Marie-Pierre Rousselot, Philippe Mahon, François-Xavier |
| Copyright Year | 2017 |
| Description | Key Points First-line or subsequent dasatinib or nilotinib can be safely stopped in CML patients with deep and long-lasting molecular responses. A suboptimal response or resistance prior to dasatinib or nilotinib is associated with significantly worse treatment-free remission. |
| Related Links | https://ashpublications.org/blood/article-pdf/129/7/846/1402375/blood742205.pdf |
| Ending Page | 854 |
| Page Count | 9 |
| Starting Page | 846 |
| DOI | 10.1182/blood-2016-09-742205 |
| Journal | Blood |
| Issue Number | 7 |
| Volume Number | 129 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2017-02-16 |
| Access Restriction | Open |
| Subject Keyword | Hematology Treatment Dasatinib Or Nilotinib Worse Suboptimal Cml Leukemia Discontinuation Journal: Blood (Vol- 100, Issue- 7) |
| Content Type | Text |
| Resource Type | Article |